{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-ZHLLDCO3/342badf0-7610-4e91-95f0-cead84069b38/PDF","dcterms:extent":"866 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-ZHLLDCO3/589bf1ca-ed79-4a2a-b23c-fa1e76f9cfa9/TEXT","dcterms:extent":"22 KB"}],"edm:TimeSpan":{"@rdf:about":"2022-2025","edm:begin":{"@xml:lang":"en","#text":"2022"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-ZHLLDCO3","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-UCB4A42Q"},{"@xml:lang":"sl","#text":"Placebo"}],"dcterms:issued":"2025","dc:creator":"Bizjak, Ela","dc:format":[{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"str. 37-40"}],"dc:identifier":["COBISSID_HOST:248504067","ISSN:2820-5014","URN:URN:NBN:SI:doc-ZHLLDCO3"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Fakulteta za farmacijo, ŠSSFD"},"dc:subject":[{"@xml:lang":"en","#text":"adipose derived mesenchymal stem cells"},{"@xml:lang":"en","#text":"atopic dermatitis"},{"@xml:lang":"sl","#text":"atopijski dermatitis"},{"@xml:lang":"sl","#text":"celice T-pomagalke tipa 2"},{"@xml:lang":"sl","#text":"Dermatitis"},{"@xml:lang":"en","#text":"filaggrin"},{"@xml:lang":"sl","#text":"filagrin"},{"@xml:lang":"sl","#text":"kožna bariera"},{"@xml:lang":"sl","#text":"Mezenhimske matične celice"},{"@xml:lang":"sl","#text":"mezenhimske matične celice maščobnega izvora"},{"@xml:lang":"en","#text":"microbiome"},{"@xml:lang":"sl","#text":"mikrobiom"},{"@xml:lang":"en","#text":"skin barrier"},{"@xml:lang":"en","#text":"T helper 2 cells"}],"dcterms:temporal":{"@rdf:resource":"2022-2025"},"dc:title":{"@xml:lang":"sl","#text":"Potencial uporabe mezenhimskih matičnih celic maščobnega izvora za zdravljenje atopijskega dermatitisa| splošno o dermatoveneroloških boleznih|"},"dc:description":[{"@xml:lang":"sl","#text":"Atopic dermatitis (AD) is a complex, chronic infl ammatory skin disease characterized by itching, infl ammation, and dryness of the skin. The causes of the disease are multifactorial and not fully understood. They involve dysfunction of the immune system, damage to the skin barrier, genetic predispositions, and changes in the skin microbiome. Various types of T cells (Th1, Th2, Th17, Th22), mast cells, and eosinophils participate in the immune response, releasing infl ammatory cytokines that cause acute and chronic infl ammation. Genetic mutations, particularly in the gene for fi laggrin, further weaken the skin barrier. Microbiome alterations, especially colonization of the skin by Staphylococcus aureus, further worsen the condition. Traditional treatment is based on corticosteroids and immunomodulators, but these have numerous side eff ects and are prone to resistance development. Recent studies have identifi ed adipose-derived mesenchymal stem cells (AD-MSCs) as a promising therapy, as their low immunogenicity and strong immunomodulatory and regenerative properties help suppress infl ammation and repair damaged skin. Moreover, their isolation is less invasive compared to other types of mesenchymal cells"},{"@xml:lang":"sl","#text":"Atopijski dermatitis (AD) je kompleksna, kronična vnetna bolezen kože, ki se izraža s srbečico, vnetjem in suhostjo kože. Vzrokov za pojav bolezni je več in niso popolnoma razjasnjeni. Vključuje motnje v delovanju imunskega sistema, poškodbe kožne bariere, genetske predispozicije in spremembe v kožnem mikrobiomu. V imunskem odzivu sodelujejo različni tipi celic T (Th1, Th2, Th17, Th22), mastociti in eozinofi lci, ki s sproščanjem vnetnih citokinov povzročajo akutno in kronično vnetje. Genetske mutacije, predvsem v genu za fi lagrin, dodatno oslabijo kožno bariero. Mikrobiomske spremembe, predvsem kolonizacija kože s Staphylococcus aureus, še poslabšajo stanje. Klasično zdravljenje temelji na kortikosteroidih in imunomodulatorjih, vendar prinaša številne neželene učinke in pogosto vodi v razvoj odpornosti. V novejših raziskavah se kot obetavna terapija pojavljajo mezenhimske matične celice maščobnega izvora (ADMSC), ki zaradi svoje nizke imunogenosti ter izrazitih imunomodulatornih in regenerativnih lastnosti zavirajo vnetje in obnavljajo poškodovano kožo, njihova izolacija pa je v primerjavi z ostalimi tipi mezenhimskih celic najmanj invazivna"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-ZHLLDCO3","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-ZHLLDCO3"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-ZHLLDCO3/342badf0-7610-4e91-95f0-cead84069b38/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:dataProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-ZHLLDCO3/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-ZHLLDCO3"}}}}